Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Short Interest Up 265.5% in June

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 108,354 shares, a growth of 265.5% from the May 31st total of 29,643 shares. Based on an average trading volume of 327,763 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the shares of the company are sold short.

Institutional Trading of Zhengye Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in Zhengye Biotechnology during the third quarter worth about $31,000. Millennium Management LLC acquired a new stake in shares of Zhengye Biotechnology during the 3rd quarter valued at approximately $38,000. WINTON GROUP Ltd purchased a new stake in shares of Zhengye Biotechnology during the 3rd quarter worth approximately $56,000. XTX Topco Ltd boosted its stake in shares of Zhengye Biotechnology by 71.4% during the 4th quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after acquiring an additional 24,697 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new stake in shares of Zhengye Biotechnology in the 2nd quarter worth approximately $174,000.

Zhengye Biotechnology Stock Performance

Shares of ZYBT stock opened at $0.71 on Monday. The business’s fifty day moving average price is $0.88 and its 200 day moving average price is $1.02. Zhengye Biotechnology has a 1-year low of $0.68 and a 1-year high of $13.08. The company has a quick ratio of 0.82, a current ratio of 1.14 and a debt-to-equity ratio of 0.03.

Zhengye Biotechnology (NASDAQ:ZYBT) last released its quarterly earnings data on Tuesday, April 28th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $3.97 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Zhengye Biotechnology presently has a consensus rating of “Sell”.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.